Assessing excellence in translational cancer research: a consensus based framework by Rajan, A. et al.
Assessing excellence in translational cancer
research: a consensus based framework
Rajan et al.
Rajan et al. Journal of Translational Medicine 2013, 11:274
http://www.translational-medicine.com/content/11/1/274
Rajan et al. Journal of Translational Medicine 2013, 11:274
http://www.translational-medicine.com/content/11/1/274RESEARCH Open AccessAssessing excellence in translational cancer
research: a consensus based framework
Abinaya Rajan1, Carlos Caldas2, Henri van Luenen1, Mahasti Saghatchian3 and Wim H van Harten1*Abstract
Background: It takes several years on average to translate basic research findings into clinical research and
eventually deliver patient benefits. An expert-based excellence assessment can help improve this process by: identi-
fying high performing Comprehensive Cancer Centres; best practices in translational cancer research; improving the
quality and efficiency of the translational cancer research process. This can help build networks of excellent Centres
by aiding focused partnerships. In this paper we report on a consensus building exercise that was undertaken to
construct an excellence assessment framework for translational cancer research in Europe.
Methods: We used mixed methods to reach consensus: a systematic review of existing translational research models
critically appraised for suitability in performance assessment of Cancer Centres; a survey among European stakeholders
(researchers, clinicians, patient representatives and managers) to score a list of potential excellence criteria, a focus
group with selected representatives of survey participants to review and rescore the excellence criteria; an expert
group meeting to refine the list; an open validation round with stakeholders and a critical review of the emerging
framework by an independent body: a committee formed by the European Academy of Cancer Sciences.
Results: The resulting excellence assessment framework has 18 criteria categorized in 6 themes. Each criterion has a
number of questions/sub-criteria. Stakeholders favoured using qualitative excellence criteria to evaluate the translational
research “process” rather than quantitative criteria or judging only the outputs. Examples of criteria include checking if
the Centre has mechanisms that can be rated as excellent for: involvement of basic researchers and clinicians in
translational research (quality of supervision and incentives provided to clinicians to do a PhD in translational research)
and well designed clinical trials based on ground-breaking concepts (innovative patient stratification, substantial fraction
of phase I/II trials, investigator-initiated trials). Critically, the framework supports reduced bureaucracy by building on
existing European evaluation systems.
Conclusions: The excellence framework is the product of an intense stakeholder consensus building exercise. It will be
piloted during an expert peer review/site visit of at least three European Comprehensive Cancer Centres. The findings
regarding content, governance and implementation can have relevance for other clinical and research fields.
Keywords: Translational research, Cancer, Excellence, Assessment, Criteria, Framework, Stakeholder consensus,
Peer-reviewBackground
Translational research can be defined as a complex pro-
cess of transforming scientific discoveries, arising from la-
boratory, early clinical, or population studies, into clinical
applications to reduce incidence, morbidity, and mortality
[1]. On average, it takes over a decade to deliver patient
benefits [2,3]. After the 2007/09 financial crisis healthcare* Correspondence: w.v.harten@nki.nl
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practices through regular benchmarking.
“In the last decade, we have begun discussing the idea
of translational research in every field of medicine
without ever clarifying exactly what this entails and
how it should be assessed.” (Researcher)
To date, no assessment framework has specifically fo-
cused on excellence along the entire continuum of trans-
lational research. Previous frameworks have focused on
criteria/questions mainly for the self-guided assessment of
the success of translational research organizations and/or
projects [5,6]. But there are a number of limitations to
those frameworks: (i) not every success may necessarily
be a sign of excellence; (ii) self-assessment is not sufficient
to benchmark the performance of different Centres.
Although success in translational research may be assessed
by the organization itself, for the sake of credibility,
excellence assessment requires an expert judgement
(preferably at an international level) that is completely
independent to the organization. Currently, no formal
framework exists that supports peer-reviewers to judge
excellence in translational research; (iii) previous frame-
works were informed by a few experts but did not engage
key stakeholders in setting criteria. Achieving excellence
in translational research relies on people from different
disciplines and functions working together to improve
overall performance. Consensus building helps achieve
common understanding, commitment and collaboration
and is recommended for criteria development [7].
This study produced an excellence assessment frame-
work that was developed using a consensus building
exercise with key stakeholder groups and experts from
the European cancer community. The framework will
be used to identify and assess excellent translational
research in a number of European Comprehensive
Cancer Centres (CCC’s) (combining basic, translational
and clinical research and patient care activities). The
framework will be thoroughly piloted with a number of
CCC’s in 2013-2014.Methods
Consensus building took 18 months using several me-
thods to fully engage stakeholder groups (See Figure 1).
These included clinicians, researchers, senior man-
agers and patient representatives, representing around
70 European organizations including: CCC’s, Cancer
Research Centres, Clinical Cancer Centres, Cancer
Units, Patient Organizations and Cancer networks.
Recruiting a small group of seven acknowledged ex-
perts to provide informed review and reflection at key
points complemented this process. Development of theexcellence assessment framework can be summarized
as follows:
 Literature reviews – The European accreditation
standards for CCC’s from the Organization of
European Cancer Institutes (OECI) and a report from
the National Cancer Institute (USA) Translational
Research Working Group (TRWG) on improving
translational research performance [8] were taken as a
starting point. A systematic literature review followed
to identify and critically appraise translational research
models most suitable for performance assessment of
CCC’s [9]. The result was a list of 59 excellence criteria
covering inputs, processes and outputs of basic,
translational and clinical research & clinical care.
 Stakeholder survey and focus group discussion –
This initial list of 59 criteria was scored by
stakeholders (N = 78) in an online survey.
Evaluation of criteria by participants identified
criteria as critical (if selected by more than 60% of
the participants as important), optional (if selected
by 40-60% of the participants as important) or not
relevant (if selected by less than 40% of the partici-
pants as important). 12 of the 59 criteria scored
critical (e.g. early stage clinical trials; effective trans-
fer of innovations from basic research to clinical
practice); 36 optional (e.g. improved Quality of Life
from innovations implemented; innovative preven-
tion services) and 11 not relevant (e.g. number of
surgical/paediatric/radiotherapeutical subspecial-
ities; number of radiotherapy units). Quantitative
criteria generally scored lower than qualitative cri-
teria. Next, a focus group was assembled with a rep-
resentative sample of survey participants (N = 30).
Paricipants clarified that the criteria that scored
critical and optional should be considered when de-
veloping excellence criteria and the criteria that
scored not relevant should be discarded with the
exception of Health Technology Assessment.
 Expert Group meeting – The updated list was sent to
an expert group (2 basic, 2 translational, 2 clinical
experts and 1 senior management expert). Their
selection reflected more than 30 years of experience
in basic, translational and/or clinical cancer research,
prestigious awards and memberships in Oncology,
significant current roles in European Comprehensive
Cancer Centres and willingness to contribute to
excellence framework development. The experts
suggested a comparative review of the adapted list
against recent external peer-reviewed evaluation re-
ports from two CCC’s (see acknowledgements) to
check if the criteria were reflected in these reports
and to what extent additional criteria can be identi-
fied. The revised list was sent back to the experts who
Figure 1 Consensus building exercise with stakeholders to derive an excellence framework for assessing translational cancer research.
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and placed them under 10 categories that shaped an
excellence assessment framework. The expert group
stressed the importance of using expert peer-review
when assessing the quality of translational research
in combination with the assessment framework be-
ing developed.
 Final validation by stakeholders – The revised version
of the assessment framework was sent to the same
stakeholders who had previously participated in the
consensus building exercise. The participants (N = 34)
made suggestions to improve criteria clarity in terms
of being to the point, having short sentences, avoiding
connectors such as “and”/”or” to make them less risky
for misinterpretation. Ultimately, stakeholder
feedback helped filter and refine the list down to 20
excellence criteria to assess excellence in translational
research in CCC’s during a peer-review process and 6
additional criteria to be considered according to the
preference of the CCC’s.
 Critical review of excellence criteria by an external
committee within an independent body, the
European Academy of Cancer Sciences (EACS) - The
excellence criteria that evolved from the stake-
holder consensus building were critically reviewed
by a committee (see endnote for the composi-
tiona) that has been formed in the EACS to give
external input and govern the excellence assess-
ment. The committee suggested minor re-
structuring to the excellence criteria. They re-
duced the criteria to 18 core excellence criteria,placed them in 6 themes and merged all add-
itional criteria with the core criteria (see Table 1).
Results
The consensus building exercise clearly identifed a need
to assess excellence in translational research based on
qualitative rather than quantitative criteria. Stakeholders
and experts felt that whilst for instance state-of-the-art
infrastructure is important to perform excellent transla-
tional research, the assessment of excellence itself should
focus more on how efficiently they are being used by the
organization and the quality of their outputs.
“The numbers of services/units or treatments required
to be assessed as “Excellent” appear to me to be
somewhat arbitrary. Quality rather than quantity
should prevail.” (Researcher)
There was unanimous support for the need to minimize
the bureaucracy of the excellence assessment and to
have an external expert-based governance system that is
independent to the organization being assessed in order
to maximize transparency. The experts suggested that
reports regularly prepared by the CCC’s for existing na-
tional and/or European level assessment programmes
should be first assessed against the excellence criteria
(Table 1). These reports contain sufficient qualitative
and especially quantitative data and only data missing in
such reports needs collecting. A European excellence as-
sessment framework can only be established if the pro-
cedure exceeds the current national accreditation efforts
Table 1 Excellence framework for assessing translational
cancer research
Excellence criteria Sub-criteria/questions to help
peer-reviewers assess cancer
centres
Theme 1. Organizational policies and strategies
Evidence for integration of Basic,
Translational, and Clinical research
with excellence in all areas
Effective communication
between multidisciplinary teams?
Centre is treating patients in at
least 3 major cancer types at an
internationally competitive level
Sufficient patient volume?
Appropriate infrastructure?
Internationally recognized
medical specialists?
Expertise level?
Mechanisms are in place for
continuous quality assurance.
Defined protocols for:
Output monitoring?
Peer review programs?
Ethical standards?
Teaching good practices?
Scientific misconduct provisions?
Theme 2. People management
Clear recruiting strategy to
promote excellence
Internationally competitive
recruiting?
Attention for gender issues?
Independence of PIs is clearly
defined
Defined institutional support for
PIs?
Incentives to improve leadership
competencies in place?
The research program of PIs is
regularly evaluated
Scientific output?
Multidisciplinary activities?
Regular site visits?
Mechanisms are in place to
involve basic researchers and
clinicians in translational research
Active participation of clinicians
in basic/translational research?
Institute clearly facilitates
participation?
Is interaction between
clinicians and basic research
effectively stimulated?
Number of clinicians participating
in MD-PhD programs during last
5 years?
Mechanisms to promote
collaboration with research teams
outside the Centre
Number and quality of joint
output?
Partners are internationally
leading?
Theme 3. Research infrastructure/competencies
Centre has internationally
competitive facilities and proven
forefront expertise in a substantial
number of key areas.
Prominence in number of the
following areas:
- Identifying, validating, and
designing rational Rx strategies
directed at key molecular cancer
targets?
- Surgery, innovative operation
theaters.
Table 1 Excellence framework for assessing
translational cancer research (Continued)
- Radiotherapy infrastructure?
- Next generation sequencing
and other “omics”?
- Bioinformatics and
computational biology (both
infrastructure and innovation)
- Robotic screening (drugs,
shRNA, siRNA)?
- Advanced microscopy facilities
(e.g. confocal, lifetime imaging,
flow cytometry etc)?
- Clinical imaging and innovative
modalities?
- Prominence in area of animal
model systems?
- State of the art biobank with
clinical informatics linked with
genomic and other data?
- Patient registry with strong
biostatistical support?
- PK, PD monitoring phase 1/2
clinical trials?
- Pharmaceutical production/
formulation?
- Production biologicals for use
in patients?
- Molecular pathology?
- Good interface with chemistry,
physics, engineering,
mathematics etc?
- Population studies and
resources such as cohorts?
- Health economics; primary care
links; early detection
programmes?
- Technology Transfer support?
- Other?
Theme 4. Clinical (trial) management
Clinical trials are well designed Number of innovative aspects:
- Has it performed
groundbreaking proof of Concept
trials? Were these based on
molecular tumor parameters?
- Innovative stratification of
patients (adaptive trial design)?
- Investigator-initiated trials?
- First in man?
- Substantial fraction of phaseI/II
trials?
- Advanced modeling (e.g. PDX)?
Centre utilizes an internal review
system to select for the most
innovative and promising
protocols.
Evidence that this has lead to
innovative trials over a 5-year
period?
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Table 1 Excellence framework for assessing
translational cancer research (Continued)
Patients enrolled in clinical trials A substantial fraction (>10%) of
patients is enrolled in phase I/II
trials?
Continuous improvement of the
quality of patient care
Appropriate monitoring with
patient participation in the
process?
Outcome is at forefront and
based on patient mix treated
Proper benchmarking?
Theme 5. Internationally recognized excellence
Research has resulted in changes
in clinical thinking and practice –
emphasis on physician
investigators.
- Examples to be listed.
- Best in class young and mid
career physician-investigator
faculty recruited and retained by
the Centre
Is the Centre training and
recruiting ever better physician/
oncologist-investigators?
The Centre has an international
reputation ranking it in the top
10% segment
Evident from:
- Output related to size and
expenditure based on
independent benchmarking
performed within last 3 years.
- Substantial impact is evident in
all three research areas (basic,
translational, clinical).
- High rating by international peers
- Prestigious collaborations
- Accreditation status
National/international awards
- Prestigious competitive grants
obtained
Theme 6. Financial expertise
Efficient financial management
and support
Appropriate support for
managing external grants and
clinical research projects
including contracts with industry.
A substantial fraction of income is
obtained through funding bodies
that employ a critical review
process.
Objective success in open
competition for grants.
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ries sufficient credibility.
“CCC’s in the European Union member states already
go through different expert based peer-reviewed
national evaluations, how are we going to justify the
need for and reduce the bureaucracy of a European
excellence assessment?” (Experts)
It was emphasised that assessing the translational research
“process” along the entire continuum from basic research
upto clinical practice and back is as critical as assessing in-
puts and especially outputs. However, it was decided thatthe assessment does not have to encompass population
based outcomes because that stage goes beyond the scope
of most European CCC’s and is the responsibility of differ-
ent authorities within the EU member states. Furthermore,
it has a very long lagtime and is influenced by several non-
institutional factors which makes it difficult to access data
on time. A focus on organizational level assessment was
preferred. However, for certain issues, such as those related
to prevention and early detection, translational research
should extend its scope beyond current organizational
boundaries to optimize its relevance on population level.
Stakeholders can be made aware of this through relevant
contacts with Europe-wide organizations such as the
European Public Health Alliance (EPHA) [10] who act as
gatekeepers to the national and regional authorities across
the EU-28 member states.
“It is important to establish an excellence assessment,
which helps assess the highest levels of translational
research quality through the innovation, productivity
and efficiency of an organization.” (Manager)
Another example of careful qualitative assessment instead
of quantitative data collection is the use of the scientific in-
frastructure that CCC’s offer to other institutions. Such cri-
teria cannot be imposed on all CCC’s as the nature of
demand depends on specific regional/national contexts.
“Of course, an excellent Centre should be willing to
make these facilities available if asked for on a
collaborative basis. But at my Centre, while we make
some of these facilities available across the rest of city,
we have not in the past five years had any requests to
make these facilities available to other Centres in the
nation because these Centres have their own access to
these facilities.” (Manager)
Finally, excellence criteria on patient-related aspects
were perceived to be specifically important.
“We must not only look at efficacy and safety in
clinical study setting but even more to the value in the
everyday practice of products/technologies/therapies.”
(Patient representative)
Discussion
By undertaking a consensus-building exercise to develop
an excellence assessment framework it was clear that while
consensus can exist at a general level, some disagreement is
unavoidable due to the different backgrounds, experiences
and interests of the stakeholder groups. For instance, clini-
cians and patient representatives felt that excellence as-
sessment does not need to involve basic research and
should focus more on clinical care, but basic researchers
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the entire continuum of translational research cannot be
fully assessed. Furthermore, the question whether the right
stakeholders and experts are involved was carefully ad-
dressed at each stage of the criteria development process.
For each excellence criterion, we considered having con-
sensus when 60% or more of the stakeholders that partici-
pated agreed and we did not consider single votes by an
individual stakeholder as sufficient. Inadvertently, some
perspectives may have been left out that might still show to
be critical. Excellence assessment requires a degree of flexi-
bility, which is possible to implement in a transparent man-
ner by using an independent peer review panel. While a
common format is desirable, rigid formats may be unsuit-
able for organizations operating in different health systems
and can introduce significant bureaucracy.
Qualitative excellence criteria increase the challenge
for objective rating. A flexible and meaningful rating sys-
tem is therefore needed. For the final decision, strengths
and weaknesses across all criteria as well as individual
criterion should be considered with an agreed minimum
score on each criterion. However, to what extent should
there be flexibility in accommodating the limitations im-
posed on individual CCC’s because they have to operate
in different European health systems? Regarding health
care, the EU operates on a subsidiarity principle. It
means that all clinical and some research fields operate
within nationally set frameworks. However, transnational
cooperation is valued to share knowledge and improve
performance and this brings some specific rules into
play. Most EU member states have competitive national
assessments but none would be easily accepted for use
in another member state. Instead, considering best prac-
tices from across all member states in identifying and
assessing excellence in translational research is far more
transparent and can give wider acceptance of such as-
sessments across the EU. Essentially, it is about an indi-
vidual Centre making its own case of why it deserves to
be designated as excellent given its own operating
enviornment. And then the peer-reviewers can check
whether the case made by the Centre is valid during a
site visit. This will be done with the help of the excel-
lence criteria (Table 1) to some extent but experts
should also be prepared to come across areas of excel-
lence that the Centre may have forgotten to mention
during its application for excellence designation. A re-
lated issue raised by some experts was about discarding
or “killing” insufficiently promising translational research
projects, because of insufficient innovation, a low chance
of clinical implementation or probably very unfavorable
cost effectiveness. Of course identifying those is a risky
matter, as it is often very difficult to predict the actual
clinical potential in early stages of research. Nevertheless
and increasingly, early stage Health Technology Assessmenttechniques are being developed and applied to aid decision
makers to decide about further research investments or re-
searchers to set the specifics/demands that the research
and development process should meet [11]. One could con-
sider looking into the availability of mechanisms to assist
early stage decision-making on adequate translational re-
search progress. It seems advisable to develop specific
knowledge and development of a norm or reference
material on this topic.
“Research is also a matter of intuition, intellectual
flexibility and aptitude to identify opportunities.
Excellence assessment must go beyond putting a tick
against criteria and needs to consider the local context
in which institutions operate.” (Manager)
For example, for high impact of publications it was
hard to establish a minimum level because it varies
greatly between the different disciplines within Oncology
and among CCC’s across the EU member states.
However, the average scores for each discipline can still
be considered to make this criterion inclusive. Further, a
range of bibliometric index other than just impact fac-
tors should be considerd i.e. citation factor, cumulative
impact factor and the quality and impact of individual
publications to be rigorously judged by an expert peer
review team.
“One publication that shows the 100% cure of a cancer
is enough. Ten publications of one-month prolongation
of survival mean nothing.” (Clinician)
In Europe, the current excellence assessment primarily
intends to evaluate team science due to the multifaceted
nature of translational research where collaboration of dif-
ferent disciplines is critical to its success. The criteria that
have emerged through the consensus building exercise,
support this statement for example by focusing on multi-
disciplinary team collaboration, communication and joint
publication efforts, participation of different department
staff in various research projects and the outputs. A spe-
cific product of work may involve biologists, medical
chemists, pharmacologists, imaging physicists and clini-
cians. Thus it can be difficult to identify the exact contri-
butions made by each single member of the team and this
could raise issues when individuals are evaluated for ten-
ure or promotions etc. However, the consensus building
exercise revealed that also monitoring individual efforts to
some extent is needed for excellence. This could help pro-
mote a competitive attitude among researchers within and
outside a Centre and help identify and reward excellent
contributions of specific researchers to science that might
otherwise go undetected. The individual efforts will be
evaluated taking into account a range of factors: the
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in translational research; the quality of the research pro-
grams of PI’s and if they are regularly evaluated; presti-
gious awards, discoveries and memberships attributed to
specific individuals from the Centre; investigator-initiated
trials and their success rate etc. Currently, national assess-
ment programs within some EU member states conduct
these evaluations but there is no formally agreed assess-
ment on European level. Finally, this consensus building
exercise revealed a need to get some obvious basics right
that might otherwise be ignored. For example, to ensure
that the criteria are both meaningful and easily understood
by organizations, words such as “high”, “well”, “minimum”,
“significant”, “cutting-edge”, “state-of-the-art”, “substantial”
etc. unless carefully explained can be easily misinterpreted
by stakeholders. Stakeholders accepted to start developing
an excellence framework with these words/definitions but
suggested refining them based on pilots.
Piloting of the excellence framework
A committee consisting of internationally respected and
renowned experts in Oncology will govern the excel-
lence assessment process. In the EU, members of the
European Academy of Cancer Sciences satisfy such re-
quirements, and international experts (from the National
Cancer Institute, USA and Accreditation Canada) will be
invited to join the committee and the official peer review
team. A Centre that applies to be assessed as excellent
should provide documentation to the committee. This
will include recent external peer reviewed evaluation re-
ports in English that the Centre has produced for na-
tional and/or international evaluations in the past
3 years, covering basic, translational and clinical areas
with specific achievements in translating innovations
from bench to bedside and/or vice versa. Further docu-
mentation may be requested if the initial material is
found insufficient. After an initial screening of the docu-
ments against excellence criteria (Table 1) the commit-
tee will decide if the Centre qualifies for site visit/peer
review in which again the excellence criteria will be used
to evaluate Centres. A minimum of three European
CCC’s will pilot the excellence framework.
Conclusions
Assessing excellence requires a mix of quantitative and
qualitative criteria retrievable through different data
sources. But we need to recognise that the consensus
building exercise showed strong support for qualitative
criteria. This is because it will build on existing evaluation
systems across the EU and other international systems
(e.g. US, Canada) that already provide the necessary
breadth of quantitative data. The assessment framework
that we have developed will need to be thoroughly tested
with European CCC’s to prove that it can help identifyexcellence in translational research. Although, the frame-
work was primarily developed for Oncology, it can prob-
ably be translated to other research and/or clinicial fields
after rigorous validation. Allocating governance to an ex-
ternal entity that has credibility and is independent of the
organizations being assessed is a key ingredient. Finally,
the success of the assessments will depend on minimized
bureaucracy and maximized transparency and account-
ability during the evaluation process.
Endnote
aThe composition of the committee formed in the
European Academy of Cancer Sciences is: Prof. Dr.
Anton Berns (Senior Group Leader Molecular Genetics,
Netherlands Cancer Institute), Prof. Dr. David M.
Livingston (Chairman, Executive Committee for Re-
search, Dana-Farber Cancer Institute and Emil Frei Pro-
fessor of Genetics and Medicine, Harvard Medical
School), Prof. Dr. Daniel Louvard (Director of Research
Centre at Institut Curie France), and Prof. Sir Bruce
Ponder (Head of Department, Oncology at University of
Cambridge, UK).
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